Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
April 11, 2022 08:30 ET
|
Lumos Pharma, Inc.
- Interim Data Anticipated by End of 2022 - - Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - AUSTIN, Texas, April 11, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma,...
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
March 23, 2022 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew,...
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
March 10, 2022 16:01 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results...
Lumos Pharma to Participate in Upcoming Investor Conferences
March 10, 2022 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
February 23, 2022 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
January 05, 2022 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma to Participate in Upcoming Investor Conferences
November 10, 2021 17:06 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
November 03, 2021 16:01 ET
|
Lumos Pharma, Inc.
Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sitesSix-month primary outcome data readout from OraGrowtH210 expected 2H 2023...
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
October 21, 2021 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma to Participate in September Investor Conferences
September 02, 2021 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...